{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:08:59Z","timestamp":1794539339353,"version":"4.9.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02120-8","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:23:42Z","timestamp":1777965822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives"],"prefix":"10.1007","volume":"26","author":[{"given":"Zahra","family":"Taghinejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-3975","authenticated-orcid":false,"given":"Nahid","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athar","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Soleimanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-079X","authenticated-orcid":false,"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"1","key":"2120_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/hematology.2021000301","volume":"2021","author":"BK Hamilton","year":"2021","unstructured":"Hamilton BK. Updates in chronic graft-versus-host disease. Hematol Am Soc Hematol Educ Program. 2021;2021(1):648\u201354.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2120_CR2","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/bmt.2013.35","volume":"48","author":"M Ayas","year":"2013","unstructured":"Ayas M, et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transpl. 2013;48(9):1168\u201372.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2120_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin E, et al. Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations. J Am Acad Dermatol. 2024;90(1):1\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2120_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","volume":"107","author":"D Niederwieser","year":"2022","unstructured":"Niederwieser D, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045\u201353.","journal-title":"Haematologica"},{"issue":"16","key":"2120_CR5","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/bloodadvances.2024013442","volume":"8","author":"M Tamaki","year":"2024","unstructured":"Tamaki M, et al. Associations between acute and chronic graft-versus-host disease. Blood Adv. 2024;8(16):4250\u201361.","journal-title":"Blood Adv"},{"issue":"8","key":"2120_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.exphem.2016.05.011","volume":"44","author":"HM Vriesendorp","year":"2016","unstructured":"Vriesendorp HM, Heidt PJ. History of graft-versus-host disease. Exp Hematol. 2016;44(8):674\u201388.","journal-title":"Exp Hematol"},{"issue":"7","key":"2120_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko CL, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report. Transplantation Cell therapy. 2021;27(7):545\u201357.","journal-title":"Transplantation Cell therapy"},{"key":"2120_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fimmu.2017.00328","volume":"8","author":"AM Flinn","year":"2017","unstructured":"Flinn AM, Gennery AR. Treatment of Pediatric Acute Graft-versus-Host Disease\u2014Lessons from Primary immunodeficiency? Front Immunol. 2017;8:328.","journal-title":"Front Immunol"},{"issue":"18","key":"2120_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/cells13181524","volume":"13","author":"A Olivieri","year":"2024","unstructured":"Olivieri A, Mancini G. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD. Cells. 2024;13(18):1524.","journal-title":"Cells"},{"key":"2120_CR10","doi-asserted-by":"publisher","first-page":"1079708","DOI":"10.3389\/fimmu.2022.1079708","volume":"13","author":"G Socie","year":"2022","unstructured":"Socie G, Michonneau D. Milestones in acute GVHD pathophysiology. Front Immunol. 2022;13:1079708.","journal-title":"Front Immunol"},{"issue":"1","key":"2120_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2120_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3324\/haematol.2011.055186","volume":"97","author":"J Pidala","year":"2012","unstructured":"Pidala J, et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2012;97(3):451\u20138.","journal-title":"Haematologica"},{"issue":"5","key":"2120_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41409-024-02245-y","volume":"59","author":"L Gorfinkel","year":"2024","unstructured":"Gorfinkel L, et al. Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD. Bone Marrow Transpl. 2024;59(5):680\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2120_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, et al. EBMT\u2009\u2013\u2009NIH\u2013CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401\u201315.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2120_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/17474086.2021.1860001","volume":"14","author":"L Giaccone","year":"2021","unstructured":"Giaccone L, et al. Biomarkers for acute and chronic graft versus host disease: state of the art. Expert Rev Hematol. 2021;14(1):79\u201396.","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"2120_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood.2023019799","volume":"142","author":"K Umino","year":"2023","unstructured":"Umino K, et al. Antibody-mediated pathogenesis of chronic GVHD through DBY\/HLA class II complexes and induction of a GVL effect. Blood. 2023;142(11):1008\u201321.","journal-title":"Blood"},{"key":"2120_CR17","doi-asserted-by":"publisher","unstructured":"Soci\u00e9 G, et al. Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. J Clin Invest. 2021;131(12):e149296. https:\/\/doi.org\/10.1172\/JCI149296","DOI":"10.1172\/JCI149296"},{"issue":"2","key":"2120_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3324\/haematol.2020.267583","volume":"107","author":"H Schmid","year":"2022","unstructured":"Schmid H, et al. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells. Haematologica. 2022;107(2):427\u201336.","journal-title":"Haematologica"},{"key":"2120_CR19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","volume":"8","author":"M Mavers","year":"2017","unstructured":"Mavers M, Maas-Bauer K, Negrin RS. Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2017;8:900.","journal-title":"Front Immunol"},{"issue":"22","key":"2120_CR20","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood.2025028504","volume":"146","author":"DM Tufa","year":"2025","unstructured":"Tufa DM, et al. Innate lymphoid cells prevent graft-versus-host disease via IL-9\u2013driven T-cell senescence. Blood. 2025;146(22):2656\u201369.","journal-title":"Blood"},{"key":"2120_CR21","doi-asserted-by":"publisher","first-page":"1045168","DOI":"10.3389\/fimmu.2022.1045168","volume":"13","author":"M Doglio","year":"2022","unstructured":"Doglio M, et al. Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease. Front Immunol. 2022;13:1045168.","journal-title":"Front Immunol"},{"issue":"3","key":"2120_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41409-023-02174-2","volume":"59","author":"O Penack","year":"2024","unstructured":"Penack O, et al. ECP versus ruxolitinib in steroid-refractory chronic GVHD \u2013 a retrospective study by the EBMT transplant complications working party. Bone Marrow Transplant. 2024;59(3):380\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2120_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","volume":"27","author":"DJ Martini","year":"2022","unstructured":"Martini DJ, Chen YB, DeFilipp Z. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. Oncologist. 2022;27(8):685\u201393.","journal-title":"Oncologist"},{"issue":"3","key":"2120_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228\u201338.","journal-title":"N Engl J Med"},{"key":"2120_CR25","doi-asserted-by":"publisher","first-page":"1241068","DOI":"10.3389\/fimmu.2023.1241068","volume":"14","author":"R Zeiser","year":"2023","unstructured":"Zeiser R, et al. Novel therapies for graft versus host disease with a focus on cell therapies. Front Immunol. 2023;14:1241068.","journal-title":"Front Immunol"},{"issue":"10","key":"2120_CR26","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.22.00509","volume":"41","author":"DB Miklos","year":"2023","unstructured":"Miklos DB, et al. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. J Clin Oncol. 2023;41(10):1876\u201387.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2120_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23(2):211\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2120_CR28","doi-asserted-by":"publisher","first-page":"1199422","DOI":"10.3389\/fimmu.2023.1199422","volume":"14","author":"LM Gail","year":"2023","unstructured":"Gail LM, et al. Complex interactions of cellular players in chronic Graft-versus-Host Disease. Front Immunol. 2023;14:1199422.","journal-title":"Front Immunol"},{"issue":"12\u2013b Suppl","key":"2120_CR29","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.18553\/jmcp.2022.28.12-b.s1","volume":"28","author":"B Flavin","year":"2022","unstructured":"Flavin B. Chronic graft-vs-host disease: Current understanding of disease and treatment landscape. J Managed Care Specialty Pharm. 2022;28(12\u2013b Suppl):S2\u201312.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"11","key":"2120_CR30","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3324\/haematol.2011.049841","volume":"96","author":"J Pidala","year":"2011","unstructured":"Pidala J, et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011;96(11):1678\u201384.","journal-title":"Haematologica"},{"key":"2120_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-020-01592-z","volume":"11","author":"C Morata-Tarifa","year":"2020","unstructured":"Morata-Tarifa C, et al. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease\u2014a meta-analysis. Stem Cell Res Ther. 2020;11:1\u201312.","journal-title":"Stem Cell Res Ther"},{"key":"2120_CR32","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3389\/fimmu.2020.01076","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, et al. Immunosuppressive property of MSCs mediated by cell surface receptors. Front Immunol. 2020;11:1076.","journal-title":"Front Immunol"},{"issue":"17","key":"2120_CR33","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.3390\/ijms22179531","volume":"22","author":"L L\u00f3pez-Garc\u00eda","year":"2021","unstructured":"L\u00f3pez-Garc\u00eda L, Castro-Manrreza ME. TNF-\u03b1 and IFN-\u03b3 participate in improving the immunoregulatory capacity of mesenchymal stem\/stromal cells: Importance of cell\u2013cell contact and extracellular vesicles. Int J Mol Sci. 2021;22(17):9531.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2120_CR34","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/stem.503","volume":"28","author":"Q-Z Zhang","year":"2010","unstructured":"Zhang Q-Z, et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010;28(10):1856\u201368.","journal-title":"Stem Cells"},{"key":"2120_CR35","doi-asserted-by":"publisher","unstructured":"Huang Y, et al. Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications. Int J Mol Sci. 2022;23(17):10023. https:\/\/doi.org\/10.3390\/ijms231710023","DOI":"10.3390\/ijms231710023"},{"issue":"1","key":"2120_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.tp.0000244572.24780.54","volume":"83","author":"R Ramasamy","year":"2007","unstructured":"Ramasamy R, et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83(1):71\u20136.","journal-title":"Transplantation"},{"issue":"10","key":"2120_CR37","first-page":"3838","volume":"99","author":"M Di Nicola","year":"2002","unstructured":"Di Nicola M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood J Am Soc Hematol. 2002;99(10):3838\u201343.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"2120_CR38","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/leu.2014.225","volume":"29","author":"Y Peng","year":"2015","unstructured":"Peng Y, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5\u2009+\u2009regulatory B cells producing interleukin 10. Leukemia. 2015;29(3):636\u201346.","journal-title":"Leukemia"},{"key":"2120_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0680-7","volume":"11","author":"P Lai","year":"2018","unstructured":"Lai P, et al. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol. 2018;11:1\u201315.","journal-title":"J Hematol Oncol"},{"key":"2120_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-019-0159-x","volume":"7","author":"K Yin","year":"2019","unstructured":"Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem\/stromal cells: a new therapeutic paradigm. Biomark Res. 2019;7:1\u20138.","journal-title":"Biomark Res"},{"issue":"1","key":"2120_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.20517\/evcna.2025.02","volume":"6","author":"B Giebel","year":"2025","unstructured":"Giebel B. A milestone for the therapeutic EV field: FDA approves Ryoncil, an allogeneic bone marrow-derived mesenchymal stromal cell therapy. Extracell Vesicles Circulating Nucleic Acids. 2025;6(1):183.","journal-title":"Extracell Vesicles Circulating Nucleic Acids"},{"issue":"12","key":"2120_CR42","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/bmt.2010.195","volume":"45","author":"J Weng","year":"2010","unstructured":"Weng J, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45(12):1732\u201340.","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"2120_CR43","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy O, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.","journal-title":"Sci Adv"},{"key":"2120_CR44","unstructured":"br t. Launch of DestroCell in Tehran Marks a New Era in Cell Therapy for Iran and Beyond. 2024; Available from: https:\/\/taskinbr.com\/launch-of-destrocell-in-tehran-marks-a-new-era-in-cell-therapy-for-iran-and-beyond\/"},{"key":"2120_CR45","unstructured":"BioSpace. Mesoblast Sets Ryoncil\u00ae Price Based on Economic Value of Treatment with Planned Product Availability This Quarter. 2025 [cited 2025 27 Feb. ]; Available from: https:\/\/www.biospace.com\/press-releases\/mesoblast-sets-ryoncil-price-based-on-economic-value-of-treatment-with-planned-product-availability-this-quarter"},{"key":"2120_CR46","unstructured":"Cade. 1st Allogeneic Cell Therapy Product Released in Japan by Mesoblast Licensee, JCR Pharmaceuticals. BioInformant. 2016 [cited 2026 5 Feb.]; Available from: https:\/\/bioinformant.com\/1st-allogeneic-cell-therapy-product-released-in-japan-by-mesoblast-licensee-jcr-pharmaceuticals"},{"issue":"1","key":"2120_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jaci.2023.09.025","volume":"153","author":"P Georgiev","year":"2024","unstructured":"Georgiev P, et al. Regulatory T cells in dominant immunologic tolerance. J Allergy Clin Immunol. 2024;153(1):28\u201341.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2120_CR48","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (Baltimore Md : 1950). 1995;155(3):1151\u201364.","journal-title":"J Immunol (Baltimore Md : 1950)"},{"issue":"4","key":"2120_CR49","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4\u2009+\u2009CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330\u20136.","journal-title":"Nat Immunol"},{"key":"2120_CR50","doi-asserted-by":"publisher","first-page":"697854","DOI":"10.3389\/fimmu.2021.697854","volume":"12","author":"W-w Guo","year":"2021","unstructured":"Guo W-w, et al. Regulatory T cells in GVHD therapy. Front Immunol. 2021;12:697854.","journal-title":"Front Immunol"},{"key":"2120_CR51","doi-asserted-by":"publisher","first-page":"1217065","DOI":"10.3389\/frtra.2023.1217065","volume":"2","author":"A Cassano","year":"2023","unstructured":"Cassano A, Chong AS, Alegre ML. Tregs in transplantation tolerance: role and therapeutic potential. Front Transpl. 2023;2:1217065.","journal-title":"Front Transpl"},{"issue":"3","key":"2120_CR52","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1084\/jem.20020090","volume":"196","author":"JL Cohen","year":"2002","unstructured":"Cohen JL, et al. CD4\u2009+\u2009CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401\u20136.","journal-title":"J Exp Med"},{"issue":"6","key":"2120_CR53","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.ymthe.2022.02.025","volume":"30","author":"S Landwehr-Kenzel","year":"2022","unstructured":"Landwehr-Kenzel S, et al. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol Ther. 2022;30(6):2298\u2013314.","journal-title":"Mol Ther"},{"issue":"22","key":"2120_CR54","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, et al. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. N Engl J Med. 2011;365(22):2055\u201366.","journal-title":"N Engl J Med"},{"issue":"11","key":"2120_CR55","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood.2021014448","volume":"139","author":"R Zeiser","year":"2022","unstructured":"Zeiser R, Lee SJ. Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood. 2022;139(11):1642\u20135.","journal-title":"Blood"},{"issue":"8\u20139","key":"2120_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00251-017-1001-y","volume":"69","author":"HG Hilton","year":"2017","unstructured":"Hilton HG, Parham P. Missing or altered self: human NK cell receptors that recognize HLA-C. Immunogenetics. 2017;69(8\u20139):567\u201379.","journal-title":"Immunogenetics"},{"issue":"8","key":"2120_CR57","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","volume":"15","author":"L Co\u00ebnon","year":"2024","unstructured":"Co\u00ebnon L, et al. Natural Killer cells at the frontline in the fight against cancer. Cell Death Dis. 2024;15(8):614.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2120_CR58","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jcyt.2024.07.013","volume":"26","author":"MP Lauener","year":"2024","unstructured":"Lauener MP, et al. Expansion and characterization of immune suppressive CD56(bright)Perforin(-) regulatory-like natural killer cells in chronic graft-versus-host disease. Cytotherapy. 2024;26(12):1472\u201383.","journal-title":"Cytotherapy"},{"issue":"1","key":"2120_CR59","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Therapy. 2024;9(1):302.","journal-title":"Signal Transduct Target Therapy"},{"key":"2120_CR60","doi-asserted-by":"publisher","first-page":"1358668","DOI":"10.3389\/fimmu.2024.1358668","volume":"15","author":"AD Hadjis","year":"2024","unstructured":"Hadjis AD, McCurdy SR. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation. Front Immunol. 2024;15:1358668.","journal-title":"Front Immunol"},{"issue":"21","key":"2120_CR61","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293\u2013301.","journal-title":"Blood"},{"key":"2120_CR62","doi-asserted-by":"publisher","unstructured":"Sheng L, et al. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation. Front Immunol. 2020;11:1534. https:\/\/doi.org\/10.3389\/fimmu.2020.01534","DOI":"10.3389\/fimmu.2020.01534"},{"issue":"6","key":"2120_CR63","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.celrep.2014.05.011","volume":"7","author":"H Ghadially","year":"2014","unstructured":"Ghadially H, et al. NK cell receptor NKp46 regulates graft-versus-host disease. Cell Rep. 2014;7(6):1809\u201314.","journal-title":"Cell Rep"},{"key":"2120_CR64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","volume":"8","author":"F Simonetta","year":"2017","unstructured":"Simonetta F, Alvarez M, Negrin RS. Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol. 2017;8:465.","journal-title":"Front Immunol"},{"issue":"1","key":"2120_CR65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12865-019-0326-8","volume":"20","author":"P Zhang","year":"2019","unstructured":"Zhang P, et al. NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme. BMC Immunol. 2019;20(1):46.","journal-title":"BMC Immunol"},{"issue":"9","key":"2120_CR66","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.clml.2016.06.013","volume":"16","author":"SY Kim","year":"2016","unstructured":"Kim SY, et al. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016;16(9):527\u2013e5352.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2120_CR67","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.leukres.2011.11.009","volume":"36","author":"M Tanaka","year":"2012","unstructured":"Tanaka M, et al. The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. Leuk Res. 2012;36(6):699\u2013703.","journal-title":"Leuk Res"},{"issue":"8","key":"2120_CR68","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"4","key":"2120_CR69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"G Suck","year":"2016","unstructured":"Suck G, et al. NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485\u201392.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2120_CR70","first-page":"e2501","volume":"28","author":"F Otegbeye","year":"2022","unstructured":"Otegbeye F, et al. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. Transplantation Cell Therapy Official Publication Am Soc Transplantation Cell Therapy. 2022;28(5):e2501\u20138.","journal-title":"Transplantation Cell Therapy Official Publication Am Soc Transplantation Cell Therapy"},{"issue":"11","key":"2120_CR71","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3324\/haematol.2017.170928","volume":"102","author":"A Kariminia","year":"2017","unstructured":"Kariminia A, et al. CD56(bright) natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica. 2017;102(11):1936\u201346.","journal-title":"Haematologica"},{"issue":"11","key":"2120_CR72","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41375-022-01701-2","volume":"36","author":"HT Greinix","year":"2022","unstructured":"Greinix HT, Ayuk F, Zeiser R. Extracorporeal photopheresis in acute and chronic steroid\u2013refractory graft-versus-host disease: an evolving treatment landscape. Leukemia. 2022;36(11):2558\u201366.","journal-title":"Leukemia"},{"issue":"7","key":"2120_CR73","first-page":"2667","volume":"112","author":"ME Flowers","year":"2008","unstructured":"Flowers ME, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. J Am Soc Hematol. 2008;112(7):2667\u201374.","journal-title":"J Am Soc Hematol"},{"issue":"6","key":"2120_CR74","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S0190-9622(99)70257-4","volume":"41","author":"KR Suchin","year":"1999","unstructured":"Suchin KR, et al. Extracorporeal photochemotherapy does not suppress T-or B-cell responses to novel or recall antigens. J Am Acad Dermatol. 1999;41(6):980\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"2120_CR75","doi-asserted-by":"publisher","first-page":"p2207","DOI":"10.3389\/fimmu.2018.02207","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang L, et al. Modulation of B cells and homing marker on NK cells through extracorporeal photopheresis in patients with steroid-refractory\/resistant graft-vs.-host disease without hampering anti-viral\/anti-leukemic effects. Front Immunol. 2018;9:p2207.","journal-title":"Front Immunol"},{"issue":"12","key":"2120_CR76","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41409-020-0952-z","volume":"55","author":"F Modemann","year":"2020","unstructured":"Modemann F, et al. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplant. 2020;55(12):2286\u201393.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2120_CR77","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","volume":"56","author":"K Maas-Bauer","year":"2021","unstructured":"Maas-Bauer K, et al. Ruxolitinib\u2013ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplant. 2021;56(4):909\u201316.","journal-title":"Bone Marrow Transplant"},{"key":"2120_CR78","doi-asserted-by":"publisher","unstructured":"Das S, et al. Advancements in graft-versus-host disease prevention in hematopoietic stem cell transplantation. Iraqi Journal of Hematology 14(1):p 135-137, 2025.https:\/\/doi.org\/10.4103\/ijh.ijh_126_24","DOI":"10.4103\/ijh.ijh_126_24"},{"issue":"2","key":"2120_CR79","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang R, et al. Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial. JAMA Oncol. 2024;10(2):220\u20136.","journal-title":"JAMA Oncol"},{"issue":"24","key":"2120_CR80","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao L, et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord\u2013derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol. 2016;34(24):2843\u201350.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2120_CR81","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.beha.2023.101520","volume":"36","author":"D Weisdorf","year":"2023","unstructured":"Weisdorf D, Jurdi NE, Holtan SG. The best GVHD prophylaxis: Or at least progress towards finding it. Best Pract Res Clin Haematol. 2023;36(4):101520.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2120_CR82","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1172\/JCI135754","volume":"130","author":"B Shrestha","year":"2020","unstructured":"Shrestha B, et al. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. J Clin Invest. 2020;130(9):4652\u201362.","journal-title":"J Clin Invest"},{"key":"2120_CR83","doi-asserted-by":"publisher","first-page":"1500177","DOI":"10.3389\/fimmu.2024.1500177","volume":"15","author":"KMN Farid","year":"2024","unstructured":"Farid KMN, et al. GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis. Front Immunol. 2024;15:1500177.","journal-title":"Front Immunol"},{"issue":"1","key":"2120_CR84","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13287-022-02751-0","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther. 2022;13(1):93.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"2120_CR85","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12185-011-0989-2","volume":"95","author":"R Herrmann","year":"2012","unstructured":"Herrmann R, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012;95(2):182\u20138.","journal-title":"Int J Hematol"},{"issue":"12","key":"2120_CR86","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/bmt.2010.195","volume":"45","author":"JY Weng","year":"2010","unstructured":"Weng JY, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45(12):1732\u201340.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2120_CR87","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3324\/haematol.2010.038356","volume":"96","author":"JA P\u00e9rez-Simon","year":"2011","unstructured":"P\u00e9rez-Simon JA, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I\/II clinical trial. Haematologica. 2011;96(7):1072\u20136.","journal-title":"Haematologica"},{"key":"2120_CR88","doi-asserted-by":"publisher","unstructured":"Kim N, et al. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I\/II Clinical Study. Int J Mol Sci. 2024;25(12):6731. https:\/\/doi.org\/10.3390\/ijms25126731","DOI":"10.3390\/ijms25126731"},{"key":"2120_CR89","doi-asserted-by":"publisher","first-page":"204062072110728","DOI":"10.1177\/20406207211072838","volume":"13","author":"MZ Shen","year":"2022","unstructured":"Shen MZ, et al. Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Ther Adv Hematol. 2022;13:20406207211072838.","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"2120_CR90","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg E, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. Stem Cells Transl Med. 2020;9(10):1190\u2013202.","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"2120_CR91","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jcyt.2017.05.002","volume":"19","author":"M Jurado","year":"2017","unstructured":"Jurado M, et al. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I\/II study. Cytotherapy. 2017;19(8):927\u201336.","journal-title":"Cytotherapy"},{"issue":"1","key":"2120_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-024-04064-w","volume":"15","author":"G Lombardo","year":"2024","unstructured":"Lombardo G, et al. Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review. Stem Cell Res Ther. 2024;15(1):1\u201313.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2120_CR93","first-page":"pCd009768","volume":"1","author":"SA Fisher","year":"2019","unstructured":"Fisher SA, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019;1(1):pCd009768.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2120_CR94","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00277-018-3384-8","volume":"97","author":"L Wang","year":"2018","unstructured":"Wang L, et al. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Ann Hematol. 2018;97(10):1941\u201350.","journal-title":"Ann Hematol"},{"issue":"1","key":"2120_CR95","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13287-021-02304-x","volume":"12","author":"T Li","year":"2021","unstructured":"Li T, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):246.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"2120_CR96","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2006-08-044529","volume":"109","author":"VH Nguyen","year":"2007","unstructured":"Nguyen VH, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109(6):2649\u201356.","journal-title":"Blood"},{"issue":"1","key":"2120_CR97","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","volume":"133","author":"P Trzonkowski","year":"2009","unstructured":"Trzonkowski P, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4\u2009+\u2009CD25+CD127- T regulatory cells. Clin Immunol. 2009;133(1):22\u20136.","journal-title":"Clin Immunol"},{"issue":"14","key":"2120_CR98","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","volume":"117","author":"M Di Ianni","year":"2011","unstructured":"Di Ianni M, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921\u20138.","journal-title":"Blood"},{"issue":"4","key":"2120_CR99","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","volume":"124","author":"MF Martelli","year":"2014","unstructured":"Martelli MF, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638\u201344.","journal-title":"Blood"},{"issue":"2","key":"2120_CR100","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-019-0618-x","volume":"54","author":"A Pierini","year":"2019","unstructured":"Pierini A, et al. The ultimate haploidentical transplantation for the elderly with high-risk acute myeloid leukemia. Bone Marrow Transplant. 2019;54(2):803\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2120_CR101","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","volume":"5","author":"A Pierini","year":"2021","unstructured":"Pierini A, et al. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 2021;5(5):1199\u2013208.","journal-title":"Blood Adv"},{"issue":"1","key":"2120_CR102","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cei.13297","volume":"197","author":"KN MacDonald","year":"2019","unstructured":"MacDonald KN, Piret JM, Levings MK. Methods to manufacture regulatory T cells for cell therapy. Clin Exp Immunol. 2019;197(1):52\u201363.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2120_CR103","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","volume":"117","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061\u201370.","journal-title":"Blood"},{"issue":"8","key":"2120_CR104","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein CG, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016;127(8):1044\u201351.","journal-title":"Blood"},{"issue":"86","key":"2120_CR105","doi-asserted-by":"publisher","first-page":"35611","DOI":"10.18632\/oncotarget.26242","volume":"9","author":"JN Kellner","year":"2018","unstructured":"Kellner JN, et al. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018;9(86):35611\u201322.","journal-title":"Oncotarget"},{"issue":"4","key":"2120_CR106","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","volume":"17","author":"A Theil","year":"2015","unstructured":"Theil A, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015;17(4):473\u201386.","journal-title":"Cytotherapy"},{"issue":"22","key":"2120_CR107","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood.V128.22.385.385","volume":"128","author":"L Johnston","year":"2016","unstructured":"Johnston L, et al. A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent\/Refractory Chronic Graft Versus Host Disease. Blood. 2016;128(22):385.","journal-title":"Blood"},{"key":"2120_CR108","first-page":"511","volume":"130","author":"S Nikiforow","year":"2017","unstructured":"Nikiforow S, et al. Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease. Blood. 2017;130:511.","journal-title":"Blood"},{"issue":"21","key":"2120_CR109","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","volume":"6","author":"JS Whangbo","year":"2022","unstructured":"Whangbo JS, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022;6(21):5786\u201396.","journal-title":"Blood Adv"},{"key":"2120_CR110","unstructured":"https:\/\/www.clinicaltrials.gov\/study\/NCT02749084"},{"issue":"Supplement 1","key":"2120_CR111","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1182\/blood-2022-163394","volume":"140","author":"MV Soares","year":"2022","unstructured":"Soares MV, et al. Phase I\/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease. Blood. 2022;140(Supplement 1):880\u20132.","journal-title":"Blood"},{"key":"2120_CR112","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT01903473"},{"key":"2120_CR113","doi-asserted-by":"publisher","unstructured":"Meyer EH, et al. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight. 2019;4(10):e127244. https:\/\/doi.org\/10.1172\/jci.insight.127244","DOI":"10.1172\/jci.insight.127244"},{"issue":"18","key":"2120_CR114","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/blood.2024026446","volume":"145","author":"EH Meyer","year":"2025","unstructured":"Meyer EH, et al. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025;145(18):2012\u201324.","journal-title":"Blood"},{"issue":"617","key":"2120_CR115","doi-asserted-by":"publisher","first-page":"eabf5264","DOI":"10.1126\/scitranslmed.abf5264","volume":"13","author":"PP Chen","year":"2021","unstructured":"Chen PP, et al. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Sci Transl Med. 2021;13(617):eabf5264.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2120_CR116","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41409-025-02553-x","volume":"60","author":"M Lysandrou","year":"2025","unstructured":"Lysandrou M, et al. Regulatory T cell therapy for Graft-versus-Host Disease. Bone Marrow Transplant. 2025;60(7):933\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2120_CR117","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.beha.2008.06.003","volume":"21","author":"KM Williams","year":"2008","unstructured":"Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21(3):579\u201396.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2120_CR118","first-page":"174","volume":"10","author":"R Fedele","year":"2012","unstructured":"Fedele R, et al. The impact of early CD4\u2009+\u2009lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus. 2012;10(2):174.","journal-title":"Blood Transfus"},{"key":"2120_CR119","doi-asserted-by":"publisher","first-page":"926550","DOI":"10.3389\/fimmu.2022.926550","volume":"13","author":"KL Hippen","year":"2022","unstructured":"Hippen KL, et al. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease. Front Immunol. 2022;13:926550.","journal-title":"Front Immunol"},{"issue":"11","key":"2120_CR120","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1172\/JCI17702","volume":"112","author":"A Trenado","year":"2003","unstructured":"Trenado A, et al. Recipient-type specific CD4\u2009+\u2009CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Investig. 2003;112(11):1688\u201396.","journal-title":"J Clin Investig"},{"issue":"2","key":"2120_CR121","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/cells13020134","volume":"13","author":"M Di Ianni","year":"2024","unstructured":"Di Ianni M, et al. Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation. Cells. 2024;13(2):134.","journal-title":"Cells"},{"issue":"8","key":"2120_CR122","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood.2024026633","volume":"145","author":"SJ Lee","year":"2025","unstructured":"Lee SJ, Zeiser R. FDA-approved therapies for chronic GVHD. Blood. 2025;145(8):795\u2013800.","journal-title":"Blood"},{"key":"2120_CR123","doi-asserted-by":"publisher","unstructured":"Godoy JAP, et al. Clinical Translation of Mesenchymal Stromal Cell Therapy for Graft Versus Host Disease. Front Cell Dev Biol. 2019;7:255. https:\/\/doi.org\/10.3389\/fcell.2019.00255","DOI":"10.3389\/fcell.2019.00255"},{"key":"2120_CR124","doi-asserted-by":"crossref","unstructured":"Cheung TS, et al. Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers. Frontiers in Immunology; 2020. pp. 11\u20132020.","DOI":"10.3389\/fimmu.2020.01338"},{"issue":"18","key":"2120_CR125","doi-asserted-by":"publisher","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","volume":"1","author":"M Hirakawa","year":"2016","unstructured":"Hirakawa M, et al. Low-dose IL-2 selectively activates subsets of CD4\u2009+\u2009Tregs and NK cells. JCI insight. 2016;1(18):e89278.","journal-title":"JCI insight"},{"key":"2120_CR126","unstructured":"Lee SJ et al. NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy."},{"issue":"9","key":"2120_CR127","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","volume":"27","author":"Z DeFilipp","year":"2021","unstructured":"DeFilipp Z, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation Cell Therapy. 2021;27(9):729\u201337.","journal-title":"Transplantation Cell Therapy"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02120-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02120-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02120-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:02:56Z","timestamp":1783645376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02120-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2120"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02120-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Using artificial intelligence (AI): We employed AI-driven tools to verify grammar and improve the scholarly quality of the text, which was predominantly authored by writers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"263"}}